About Us

Trapelo was created by Intervention Insights, a company dedicated to improving outcomes for cancer patients.

 

Almost everyone at Intervention Insights has a story about a loved one or friend who has been touched by cancer. Our mission is to address the challenges that result from rapid changes in the science, technology and business of next-generation cancer care. To us, that means always putting patients first.

 

We believe Trapelo is a win-win solution for doctors, labs and payors that need real-time, evidence-based information and full transparency to make patient-based decisions. Everyone wants the best care for late-stage cancer patients. By providing access to the latest clinical evidence and facilitating network-wide collaboration, Trapelo makes it possible.
 

Intervention Insights Announces Trapelo™

Leadership Team

Clynt Taylor, Chief Executive Officer

Clynt Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.

 

Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth - including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions. Clynt is married with four children and lives in the Dallas area.

Russ Ingersoll, Chief Product Officer

Russell Ingersoll joined Intervention Insights in August, 2010, bringing 15 years of healthcare information technology experience and proven success with the design and commercialization of information-based technology products for the clinical and life science industries.

 

Prior to joining Intervention Insights, Mr. Ingersoll served as VP of Product Development for MedTrust Online, an oncology-centric information portal; Senior Director of Business Development at Phylogeny, Inc., a functional genomics services company; co-Founder of Folio Biosciences, a biobank of clinically annotated specimens and co-founder of BioProtocol, an interactive laboratory protocol system for the research community.

 

Mr. Ingersoll received a BS in Molecular and Cellular Biology from the University of Arizona, a PhD in Pharmacology and Toxicology from the University of Arizona College of Pharmacy and completed his post-doctoral training at the University of California, Berkeley.

Ephraim Hochberg, M.D., Chairman, Editorial Board and Sr. Clinical Advisor

Dr. Hochberg serves as a Senior Clinical Advisor and Chairman of the Editorial Board of Intervention Insights. Dr. Hochberg received his MD from Case Western Reserve University School of Medicine, Ohio in 1996. He completed an internship and residency at Brigham and Women’s Hospital, followed by a fellowship at the Dana Farber Cancer Institute. Dr. Hochberg is an Assistant Professor of Medicine at Harvard Medical School and is an attending physician at the Massachusetts General Hospital. He serves as the Clinical Director of Inpatient Oncology at the Massachusetts General Hospital Cancer Center.

 

With over 50 peer-reviewed publications and book chapters, he directs his research efforts towards novel therapies for Hodgkin and non-Hodgkin lymphomas. Additionally, he is a member of the NCCN Guideline Panel for Hodgkin Lymphoma.

Janine Morales, Ph.D., Director of Clinical Knowledge Management

Ms. Morales joined the Intervention Insights team in 2011 and oversees a team of editors and curators with deep expertise in molecular oncology. Her group is responsible for maintaining the company’s clinical information asset, a comprehensive knowledgebase summarizing published data pertaining to molecular biomarkers as predictors of response to targeted therapies in oncology. Ms. Morales also led the development of Intervention Insights’ framework for the systematic evaluation and synthesis of molecular clinical evidence as well as the principles guiding the presentation of molecular evidence in patient specific reports.

 

She brings 15 years of editorial and information management experience in the biotech and medical sectors and was a member of research and development teams at Elan Corp. and DNAX Research Institute (acquired by Merck & Co).

 

Ms. Morales received a BS in Biochemistry from the University of Rochester and earned her PhD in Pharmacology from the University of California, San Francisco.

E. Jerome Madison, VP Provider Relations

Jerome Madison is a 14-year veteran of the precision cancer movement who has led the most successful companies in the genomic testing space to become market leaders. He helped create best practices for market access and adoption of clinical genomics and bring his vast network and knowledge to Intervention Insights to develop the network of providers to launch Trapelo. In addition to leading start-ups and building people in the industry, Jerome is also a certified executive coach, a published author and keynote speaker on the topic of innovation.

Karan Cushman, Chief Marketing Officer

Karan Cushman is a marketing, design, and user experience veteran who has spent more than two decades immersed in the health, life science and biomedical industries. As CEO of Cushman Creative, her award-winning work in these industries has been recognized globally for driving engagement, support, and enduring loyalty. Karan’s extensive experience ranges from work with life science leaders like Genzyme and Vertex to biotech startups like Novo Biosciences. She has helped non-profit research institutions like The Jackson Laboratory grow into their own and international life science conglomerates like Lonza evolve over and over. She has also work with major consumer brands, including Coca-Cola and Delta.

Board of Directors

Wright Steenrod, Director

Mr. Steenrod joined Chrysalis as an Associate in 2001 and today leads the Technology Group. Bringing his own entrepreneurial management experiences to the Chrysalis team, Wright previously worked as a senior business development executive at a rapidly growing company preparing to go public, and served as CFO of a start-up technology transfer company where he set strategic plans and raised equity and debt capital. Wright has worked with the management teams of fourteen of Chrysalis’ investments including Digitalsmiths (sold to TiVo), Advanced Academics (sold to DeVry), Genscape (sold to GFI) and Appriss (sold to Bain Capital), in the Technology portfolio among others. He currently is a Director of Cybera, Regent Education, Straighterline, Xlerant and meQuilibrium.

 

From 1995 to 1998, Wright worked at SunTrust Bank in Atlanta as an Associate in Mergers and Acquisitions. Prior to SunTrust, he served five years in the US Marine Corps where he attained the rank of Captain.

Wright has a BA in Economics from Princeton University.

A Louisville native, Wright is active in the community working with organizations such as the Boys and Girls Clubs of Kentuckiana and Kentuckiana Works.

Michael Gross, Director

Mr. Gross is responsible for investment sourcing, deal execution and portfolio management, specifically for the InvestMichigan! Growth Capital Fund. He focuses on the healthcare and medical technology sectors and has expertise in medical devices, diagnostics, life science research, drug delivery, healthcare providers and outsourced services. Mr. Gross serves as a board director for Beringea portfolio companies Molecular Imaging, gloStream, Delphinus Medical Technologies, InTouch Health, Intervention Insights and Relume Technologies and is a board observer for Pioneer Surgical Technology and MedVantx.

 

Prior to joining Beringea, Mr. Gross was a Vice President of investment banking with P&M Corporate Finance (PMCF). While at PMCF, he led M&A transactions and capital raises for companies in the life sciences, healthcare and outsourced business services sectors.

 

Before working at PMCF, Mr. Gross worked in the investment banking group at Stout Risius Ross, Inc. He is a CFA charterholder and earned a BA in Finance from Michigan State University.

Clynt Taylor, Director and CEO

Clynt Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.

 

Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth - including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions. Clynt is married with four children and lives in the Dallas area.

Mark Olesnavage, Observer

Mr. Olesnavage has led Hopen Life Sciences since 2006. A veteran of the pharmaceutical and nutraceutical industries, he has held senior management positions in business divisions in the United States, Europe and the Pacific Rim. He spent 24 years with Perrigo Company, where he held various senior management positions, including Executive Vice President and General Manager. During his tenure, he was involved in several key acquisitions and saw the company’s sales grow from $70 million to $1.3 billion (in 2005). Mr. Olesnavage also was a driver in the development of numerous product and technology partnerships. He was previously a longtime member of the Generic Pharmaceutical Association and the Consumer Healthcare Products Association and has served on the executive committee of both groups. Prior to Perrigo, he held international marketing positions with Amway Corp.

Charlie Crawford, Observer

Mr. Crawford is an Associate at Chrysalis Ventures. He works with the management teams of existing Chrysalis investments across the firm’s focus areas of healthcare and technology and is currently a Director of Chrysalis’ portfolio company, NextImage Medical. Mr. Crawford is also actively involved in identifying new investment opportunities for Chrysalis.

 

Prior to Chrysalis, Mr. Crawford worked as a Senior Analyst at Innova Memphis, a Tennessee-based venture capital firm, where he was involved in the firm’s investments in healthcare services, technology and medical devices.

Mr. Crawford received his BA with Honors from Williams College.

Editorial Board

Ephraim Hochberg, MD
Mass General Hospital, Harvard Medical School

Alice Shaw, MD, PhD
Mass General Hospital, Harvard Medical School

Aditya Bardia, MBBS, MPH
Mass General Hospital, Harvard Medical School

Wolfram Goessling, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School

Paul A. Bunn, Jr., MD
University of Colorado Cancer Center

Harriet M. Kluger, MD
Yale University Cancer Center

Anna F. Farago, MD, PhD
Mass General Hospital, Harvard Medical School

Lead Investors

PHONE  617.250.7572

FAX  888.972.5991

EMAIL info@interventioninsights.com

800 District Ave, Suite 310
Burlington, MA 01803

Google Map »

icon-linkedin.png
TwitterIcon_Bird_Only2.png
YouTube_Icon_Only_Orange_Trans.png

Copyright 2019 Intervention Insights. All rights reserved. Privacy Policy